Search for: "Par Pharmaceutical, Inc." Results 121 - 140 of 171
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Oct 2008, 12:14 pm
" At least thee companies (Par Pharmaceutical Companies, MBIA and Blockbuster) have committed to providing an advisory vote in 2009; A number of companies where shareholders have approved say on pay have not implemented the practice. [read post]
29 Jul 2013, 4:00 am by Administrator
Le Blogue du CRLUne substitution de sûreté peut être obtenue par ordonnance de sauvegardeDans Sarailis c. [read post]
5 Apr 2007, 5:39 am
Par Pharmaceutical, Inc., 2006 WL 901657, at *4 (W.D. [read post]
20 Mar 2009, 2:05 am
Sterling Drug, Inc., 416 F.2d 417, 426 (2d Cir. 1969).District of Columbia: McNeil Pharmaceutical v. [read post]
8 May 2009, 8:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: []   Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs)   General Alicia Greenidge to step down as Director of IFPMA (Intellectual Property Watch) Flu crisis could lead to compulsory licences (Managing… [read post]
2 Nov 2007, 11:00 pm
: (PLI), (PatentDocs), (Patent Baristas), (Patently'O), Vonage settles patent dispure with Verizon: (IP Law360), Celgene and Novartis file extended release Ritalin suit: (IP Law360), T-Mobile USA is the latest to settle charges that it infringed technology for computerized sales methods held by patent-holding company Orion IP LLC: (IP Law360),Bayer beats Dr Reddy's on Avelox (moxifloxacin): (OrangeBookBlog), (Generic Pharmaceuticals), Martek obtains permanent injunction agains… [read post]
1 Nov 2017, 4:00 am by Administrator
TD Canada Trust, 2017 SCC 51 [1] A pharmaceutical company was the victim of a fraudulent cheque scheme implemented by one of its employees. [read post]
6 Apr 2011, 12:18 am by Marie Louise
427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog) Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs) Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog) Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin patents survive patent… [read post]
11 Feb 2013, 6:00 am by Rebecca Shafer, J.D.
  Of course self-insured employers do not set out to get sub-par results from the adjusters. [read post]
7 Sep 2011, 4:22 am by Marie Louise
Apotex (Patently-O) Glivec (Imatinib mesylate) – India: The Glivec patent saga – its raining recusals (Spicy IP) Glivec (Imatinib mesylate) – India: Supreme Court to hear Novartis challenge to India’s patent law (IP Watch) Lo Loestrin Fe (Norethindrone acetate / Ethinyl estradiol / Ferrous fumarate) – US: Warner Chilcott files patent infringement complaint against Lupin in response to Para IV certification (Patent Docs) Lumigan (Bimatoprost) – US: Allergan files… [read post]
27 Mar 2009, 8:00 am
(Intellectual Property Watch) Two final thoughts on big pharma acquisitions (IP finance) Brazil: Patent term cutbacks in Brazil and pharmaceutical pipelines – IP Think Tank podcast 23 March 2009 (IP Think Tank) Brazil: Patent term cutbacks - Lobbying, intellectual property and superior courts (IP Think Tank) Brazil: Patent term extension (PTE) under TRIPs revisited and reviewed by Superior Court of Justice (IP tango) Denmark: Harmonisation in Denmark: Patents covering… [read post]
9 Apr 2007, 7:30 am
From the FDA News item entitled "FDA Announces Voluntary Withdrawal of Pergolide Products":The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of pergolide manufactured by Par and Teva. [read post]
21 Mar 2018, 1:34 pm by Pierre T. Nguyen
Une de ces unicités a récemment refait surface dans la décision du Federal Circuit dans Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc.: la mise en vente pouvant faire anticiper un dépôt de brevet américain. [read post]